Business Context and Reporting Period
Company: Disc Medicine, Inc. (Nasdaq: IRON)
Filing Type: Form 8-K (Current Report)
Date of Report: March 31, 2023
Reporting Period: The filing announces financial results for the quarter and fiscal year ended December 31, 2022. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This Form 8-K serves as a notification of the release of financial results but does not contain specific numerical data within the text provided. The actual figures for revenue, profit, cash flow, margins, debt, and liquidity are contained in the press release furnished as Exhibit 99.1, which is not included in the source text. Therefore, the filing text does not provide a clear value for any specific financial metric.
Material Changes
The filing does not detail specific material changes in financial performance or operations within the body of the report. It references the announcement of results for the period ended December 31, 2022, but defers all quantitative comparisons to the attached press release.
Guidance, Outlook, and Corporate Events
- Annual Meeting: The 2023 Annual Meeting of Stockholders is scheduled for Friday, June 9, 2023, at 9:00 a.m. Eastern Time.
- Meeting Format: The meeting will be conducted as a virtual live webcast.
- Record Date: April 14, 2023.
- Shareholder Proposals: Due to no annual meeting being held the previous year, the deadline for stockholder notices of business or director nominations is April 10, 2023. The deadline for Rule 14a-8 proposals is also April 10, 2023.
- Management Commentary: No specific commentary on outlook or risks is provided in the 8-K text itself; investors are directed to the press release for the corporate update.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for the quarter and year ended December 31, 2022.
- Verify the Company's cash runway and burn rate as disclosed in the full financial statements referenced in the press release.
- Confirm the status of any ongoing clinical trials or regulatory milestones mentioned in the corporate update.
- Check the proxy statement for details on director nominees and executive compensation once released.